US Drugmaker Begins Late-Stage Testing of Single-Dose COVID-19 Vaccine in US
U.S. pharmaceutical giant Johnson & Johnson has begun late-stage human trials of a single-dose COVID-19 vaccine in the United States. Dr. Paul Stoffels, Johnson & Johnson’s chief scientific officer, told reporters Wednesday that 60,000 participants have begun receiving the vaccine across 215 locations in the United States, as well as internationally in Argentina, Brazil, Chile, Colombia, Mexico, Peru and South Africa. Dr. Stoffels said Johnson & Johnson moved into the late-stage trial after seeing positive results from its combined Phase 1 and 2 trials in the U.S. and Belgium. The Johnson & Johnson vaccine is the fourth potential coronavirus vaccine undergoing large-scale Phase 3 testing in the United States, joining Moderna, AstraZeneca and a joint effort by Pfizer and German-based BioNTech. All four efforts are being developed under the Trump administration’s President Donald Trump…